leadf
logo-loader
viewAmryt Pharma PLC

Amryt Pharma generates 'significant' top line and bottom line metrics in 1Q of this year

Amryt Pharma PLC (LON:AMYT) CEO Joe Wiley tells Proactive the commercial-stage biopharmaceutical company's 1Q revenues rose by 30% to US$44.6mln from US$34.3mln in the corresponding period of 2019.

Wiley says it's also the first time the group has become EBITDA positive, generating $4.6M in EBITDA and cash of $6.2M.

Quick facts: Amryt Pharma PLC

Price: 207 GBX

AIM:AMYT
Market: AIM
Market Cap: £336.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt Pharma announces 'positive' results from rare skin disease trial

Amryt Pharma PLC's (NASDAQ:AMYT) (LON:AMYT) Joe Wiley talks to Proactive London's Katie Pilbeam after revealing 'positive results' from the phase III success of FILSUVEZ, a gel for a rare and extremely painful skin condition called epidermolysis bullosa (EB). The results showed which products...

3 weeks, 1 day ago

2 min read